Brain natriuretic peptide between traditional and nontraditional risk factors in hemodialysis patients: Analysis of cardiovascular mortality in a two-year follow-Up

Nephron - Clinical Practice

Volumn 119, Issue 2, 2011, Pages

  Selim, G ^a   Stojceva Taneva, O ^a   Spasovski, G ^a   Georgievska Ismail, L ^a   Zafirovska Ivanovska, B ^a   Gelev, S ^a   Dzekova, P ^a   Trajcevska, L ^a   Trojacanec Piponska, S ^a   Sikole, A ^a  

^a SS CYRIL AND METHODIUS UNIVERSITY   (Macedonia)

Author keywords

Brain natriuretic peptide; C reactive protein; Cardiovascular mortality; Hemodialysis

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD PRESSURE FLUCTUATION; BODY MASS; CALCIUM DEFICIENCY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; MORTALITY; PHOSPHATE DEFICIENCY; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; UREMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK FACTORS; ROC CURVE; YOUNG ADULT;

EID: 79960277592     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000327615     Document Type: Article

References (43)

1. US Renal Data System: Atlas of End-Stage Renal Disease in the United States. USRDS 2004 Annual Data Report. National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, National Institutes of Health, 2004.
2. Collins AJ: Cardiovascular mortality in endstage renal disease. Am J Med Sci 2003; 325: 163-167. (Pubitemid 36437989)
3. Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, Klag MJ: Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: The CHOICE Study. J Am Soc Nephrol 2002; 13: 1918-1927. (Pubitemid 34700618)
4. Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A, Lewis J, Rocco M, Toto R, Windus D, Ornt D, Levey AS, HEMO Study Group: Cardiac diseases in maintenance hemodialysis patients: Results of the HEMO Study. Kidney Int 2004; 65: 2380-2389. (Pubitemid 38670024)
5. Zoccali C, Tripepi G, Mallamaci F: Predictors of cardiovascular death in ESRD. Semin Nephrol 2005; 25: 358-362.
6. Johnson DW, Craven A-M, Isbel NM: Modification of cardiovascular risk in hemodialysis patients: An evidence-based review. Hemodial Int 2007; 11: 1-14. (Pubitemid 46128673)
7. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimbürger O, Massy Z: Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: How do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 2008; 3: 505-521.
8. Levin ER, Gardner DG, Samson WK: Natriuretic peptides. N Engl J Med 1998; 339: 321-328. (Pubitemid 28366422)
9. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, Mc-Cullough PA: Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161-167. (Pubitemid 34764819)
10. Groenning BA, Raymond I, Hildebrandt PR, Nilsson JC, Baumann M, Pedersen F: Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma Nterminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart 2004; 90: 297-303. (Pubitemid 38250725)
11. Hobbs FD, Davis RC, Roalfe AK, Hare R, Davies MK, Kenkre JE: Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: Cohort study in representative and high risk community populations. BMJ 2002; 324: 1498.
12. Davis M, Espiner E, Richards G, Billings J, Town I, Neill A, Drennan C, Richards M, Turner J, Yandle T: Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 1994; 343: 440-444. (Pubitemid 24059585)
13. Ishizaka Y, Yamamoto Y, Fukunaga T, Yokota N, Kida O, Kitamura K, Kangawa K, Minamino N, Matsuo H, Eto T: Plasma concentration of human brain natriuretic peptide in patients on hemodialysis. Am J Kidney Dis 1994; 24: 461-472. (Pubitemid 24277943)
14. Mallamaci F, Zoccali C, Tripepi G, Benedetto FA, Parlongo S, Cataliotti A, Cutrupi S, Giacone G, Bellanuova I, Stancanelli B, Malatino LS: Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int 2001; 59: 1559-1566. (Pubitemid 32281248)
15. Sommerer C, Giannitsis E, Schwenger V, Zeier M: Cardiac biomarkers in haemodialysis patients: The prognostic value of aminoterminal pro-B-type natriuretic peptide and cardiac troponin T. Nephron Clin Pract 2007; 107:c77-c81. (Pubitemid 350073611)
16. Daugirdas JT: Second generation logarithmic estimates of single-pool variable volume Kt/V: An analysis of error. J Am Soc Nephrol 1993; 4: 1205-1213.
17. Daugirdas JT: Simplified equations for monitoring Kt/V, PCRn, eKt/V, and PCRn. Adv Ren Replace Ther 1995; 2: 295-304.
18. Leblanc M, Charbonneau R, Lalumiere G, Cartier P, Deziel C: Postdialysis urea rebound: Determinants and influence on dialysis delivery in chronic hemodialysis patients. Am J Kidney Dis 1996; 27: 253-261. (Pubitemid 26055139)
19. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N: Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol 1986; 57: 450-458. (Pubitemid 16119719)
20. Mark PB, Stewart GA, Gansevoort RT, Petrie CJ, McDonagh TA, Dargie HJ, Rodger RSC, Jardine AG: Diagnostic potential of circulating natriuretic peptides in chronic kidney disease. Nephrol Dial Transplant 2006; 21: 402-410. (Pubitemid 43159995)
21. Roberts MA, Srivastava PM, Macmillan N, Hare DL, Ratnaike S, Sikaris K, Ierino FL: Btype natriuretic peptides strongly predict mortality in patients who are treated with long-term dialysis. Clin J Am Soc Nephrol 2008; 3: 1057-1065.
22. Zoccali C, Mallamaci F, Benedetto FA, Tripepi G, Parlongo S, Cataliotti A, Cutrupi S, Giacone G, Bellanuova I, Cottini E, Malatino LS: Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 2001; 12: 1508-1515. (Pubitemid 32666334)
23. Naganuma T, Sugimura K, Wada S, Yasumoto R, Sugimura T, Masuda C, Uchida J, Nakatani T: The prognostic role of brain natriuretic peptides in hemodialysis patients. Am J Nephrol 2002; 22: 437-444. (Pubitemid 36158501)
24. Wang AY, Lai KN: Use of cardiac biomarkers in end-stage renal disease. J Am Soc Nephrol 2008; 19: 1643-1652.
25. Lee SW, Song JH, Kim GA, Lim HJ, Kim MJ: Plasma brain natriuretic peptide concentration on assessment of hydration status in hemodialysis patient. Am J Kidney Dis 2003; 41: 1257-1266. (Pubitemid 36637982)
26. Sheen V, Bhalla V, Tulua-Tata A, Bhalla MA, Weiss D, Chiu A, Abdeen O, Mullaney S, Maisel A: The use of B-type natriuretic peptide to assess volume status in patients with end-stage renal disease. Am Heart J 2007; 153: 244.e1-244.e5.
27. Fagugli RM, Palumbo B, Ricciardi D, Pasini P, Santirosi P, Vecchi L, Pasticci F, Palumbo R: Association between brain natriuretic peptide and extracellular water in hemodialysis patients. Nephron Clin Pract 2003; 95:c60-c66.
28. Goldsmith D, Covic A: Blood pressure control in CKD stage 5D patients -are we more or less certain what to do in 2009? Nephrol Dial Transplant 2009; 14: 3597-3601.
29. Codognotto M, Piccoli A: The use of B-type natriuretic peptide to assess volume status in dialysis patients. Am Heart J 2007; 154:e31. (Pubitemid 47632506)
30. Cataliotti A, Malatino LS, Jougasaki M, Zoccali C, Castellino P, Giacone G, Bellanuova I, Tripepi R, Seminara G, Parlongo S, Stancanelli B, Bonanno G, Fatuzzo P, Rapisarda F, Belluardo P, Signorelli SS, Heublein DM, Lainchbury JG, Leskinen HK, Bailey KR, Redfield MM, Burnett JC Jr: Circulating natriuretic peptide concentrations in patients with end-stage renal disease: Role of brain natriuretic peptide as a biomarker of ventricular remodeling. Mayo Clin Proc 2001; 76: 1111-1119. (Pubitemid 33032388)
31. Apple FS, Murakami MM, Pearce LA, Herzog CA: Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. Clin Chem 2004; 50: 2279-2285. (Pubitemid 39552162)
32. Satyan S, Light RP, Agarwal R: Relationships of N-terminal pro-B-natriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. Am J Kidney Dis 2007; 50: 1009-1019. (Pubitemid 350122814)
33. Mallamaci F, Tripepi G, Cutrupi S, Malatino LS, Zoccali C: Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. Kidney Int 2005; 67: 2330-2337. (Pubitemid 41623394)
34. Jacobs LH, van de Kerkhof JJ, Mingels AM, Passos VM, Kleijnen VW, Mazairac AH, van der Sande FM, Wodzig WK, Konings CJ, Leunissen KM, van Dieijen-Visser MP, Kooman JP: Inflammation, overhydration and cardiac biomarkers in haemodialysis patients: A longitudinal study. Nephrol Dial Transplant 2010; 25: 243-248.
35. Yeun JY, Levine RA, Mantadilok V, Kaysen GA: C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000; 35: 469-476. (Pubitemid 30124077)
36. Stenvinkel P, Wanner C, Metzger T, Heimburger O, Mallamaci F, Tripepi G, Malatino L, Zoccali C: Inflammation and outcome in end-stage renal failure: Does female gender constitute a survival advantage? Kidney Int 2002; 62: 1791-1798. (Pubitemid 35286288)
37. Kessler M, Zannad F, Lehert P, Grünfeld JP, Thuilliez C, Leizorovicz A, Lechat P, FOSIDIAL Investigators: Predictors of cardiovascular events in patients with end-stage renal disease: An analysis from the Fosinopril in dialysis study. Nephrol Dial Transplant 2007; 22: 3573-3579. (Pubitemid 350212486)
38. Panichi V, Rizza GM, Paoletti S, Bigazzi R, Aloisi M, Barsotti G, Rindi P, Donati G, Antonelli A, Panicucci E, Tripepi G, Tetta C, Palla R, RISCAVID Study Group: Chronic inflammation and mortality in haemodialysis: Effect of different renal replacement therapies. Results from the RISCAVID Study. Nephrol Dial Transplant 2008; 23: 2337-2343. (Pubitemid 351957592)
39. de Mutsert R, Grootendorst DC, Axelsson J, Boeschoten EW, Krediet RT, Dekker FW, NECOSAD Study Group: Excess mortality due to interaction between protein-energy wasting, inflammation and cardiovascular disease in chronic dialysis patients. Nephrol Dial Transplant 2008; 23: 2957-2964.
40. Wahl HG, Graf S, Renz H, et al: Elimination of the cardiac natriuretic peptides B-type natriuretic peptide (BNP) and N-terminal proBNP by hemodialysis. Clin Chem 2004; 50: 1071-1074. (Pubitemid 38725801)
41. Racek J, Králová H, Trefil L, Rajdl D, Eiselt J: Brain natriuretic peptide and N-terminal proBNP in chronic haemodialysis patients. Nephron Clin Pract 2006; 103: 162-172.
42. Clerico A, Fontana M, Zyw L, et al: Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: A systematic review. Clin Chem 2007; 53: 813-822. (Pubitemid 46744235)
43. Grootendorst DC, de Jager DJ, Brandenburg VM, Boeschoten EW, Krediet RT, Dekker FW, NECOSAD Study Group: Excellent agreement between C-reactive protein measurement methods in end-stage renal disease patients -no additional power for mortality prediction with high-sensitivity CRP. Nephrol Dial Transplant 2007; 22: 3277-3284. (Pubitemid 350202555)